Start Your Search
P2.17 - Treatment of Locoregional Disease - NSCLC (Not CME Accredited Session) (ID 966)
- Event: WCLC 2018
- Type: Poster Viewing in the Exhibit Hall
- Presentations: 1
- Coordinates: 9/25/2018, 16:45 - 18:00, Exhibit Hall
P2.17-05 - Consolidation Chemotherapy in Patients with Locally Advanced Non-Small Cell Lung Cancer After Concurrent Chemoradiotherapy (ID 14093)
16:45 - 18:00 | Author(s): Ferit Aslan
The effect of consolidation chemotherapy after concurrent chemoradiotherapy (CRT) is controversial in patients with locally advanced non-small cell lung cancer (NSCLC). In this study we aimed to compare the impact of consolidation chemotherapy after concurrent CRT and concurrent CRT alone on survival outcome and safety in patients with locally advanced NSCLC.
We retrospectively analyzed 136 patients with unresected locally advanced NSCLC that received consolidation chemotherapy after concurrent CRT and concurrent CRT alone between October 2009 and March 2018, in a single center. The groups were compared regarding overall survival (os), progression-free survival (pfs) and toxicities.4c3880bb027f159e801041b1021e88e8 Result
In our study, 120 patients were (88.2%) male and the median age was 63 (42-82). The most seen histologic types of tumor was squamous cell cancer (SCC- 63.2%). Among 136 patients; 77 patients (56.6%) received consolidation chemotherapy after concurrent CRT, 59 (43.4%) patients received concurrent CRT alone. The median PFS was 12.8 months and the median OS was 25.2 months for all patients. The median PFS was 12.8 months and 12.3 months for consolidation group and concurrent CRT group, respectively (p=0.80). The median OS was 23.6 months and 27 months for consolidation group and concurrent CRT group, respectively (p=0.84). There was no significant difference between two groups regarding PFS or OS.
Considering all the patients, there was no grade 3-4 toxicities excluding cytopenia. We reported the toxicities that nausea (77.2%), vomiting (76.5%), fatique (81.6%), mucositis ( 28.7%), stomatitis (18.1%), neuropathy (27.2%), neutropenia (39.7%), trombocytopenia (% 9.6), anemia (24.3%), febrile neutropenia (5.9%), When we compare two groups regarding treatment-related toxicities, there was no significant difference between two goups.
In the present study, our results revealed that the patients treated with consolidation chemotherapy after concurrent CRT had no better outcomes than treated with concurrent CRT alone.
Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.